Efficacy and Safety of Nintedanib and Docetaxel in Patients with Lung Adenocarcinoma: A Multicenter Real-world Analysis

This study aimed to evaluate the efficacy and safety of nintedanib and docetaxel in patients with advanced/metastatic lung adenocarcinoma in different lines of treatment. We used progression-free survival (PFS) and best objective response as primary endpoints for measuring the effectiveness. Overall survival was our secondary endpoint, as well as the safety profile.